ISONIAZID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C6H7N3O
Molecular Weight	137.1395
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

c1cnccc1C(=O)NN

InChI

InChIKey=QRXWMOHMRWLFEY-UHFFFAOYSA-N

InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)

HIDE SMILES / InChI

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1553312b-ed76-421c-a055-2579bdcf366c#i4i_indications_id_indications
Curator's Comment:: Description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00951 http://www.rxlist.com/isoniazid-drug.htm

Isoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically M. tuberculosis, M. bovis and M. kansasii. Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. Isoniazid is a prodrug and must be activated by bacterial catalase. Isoniazid inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor. The most frequent adverse reactions to isoniazid are those affecting the nervous system and the liver.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Enoyl-[acyl-carrier-protein] reductase 4 Target ID: CHEMBL1849 Sources: http://www.drugbank.ca/drugs/DB00951	Binding Agent 994		0.75 nM [Ki]
Catalase-peroxidase 2 Target ID: P9WIE4\|\|\|Q50553 Gene ID: NA Gene Symbol: katG Target Organism: Mycobacterium tuberculosis (strain CDC 1551 / Oshkosh) Sources: http://www.drugbank.ca/drugs/DB00951	Substrate 609

Conditions

Condition	Modality	Targets	Highest Phase	Product
Tuberculosis 80 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1553312b-ed76-421c-a055-2579bdcf366c	Curative		Approved 7997	Isoniazid Approved Use all forms of tuberculos in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Also is recommended as preventive therapy Launch Date 2.73024E10

C_max

Value	Dose	Analyte	Population
8.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
7.7 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg 2 times / week multiple, oral dose: 15 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
2.8 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 μg/kg bw 1 times / day multiple, oral dose: 5 μg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
16.6 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
37.81 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
53.17 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg 2 times / week multiple, oral dose: 15 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6.96 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
9.71 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 μg/kg bw 1 times / day multiple, oral dose: 5 μg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
71.52 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	15 mg/kg bw 2 times / week multiple, oral dose: 15 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
11.06 ng × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25224007/	5 mg/kg bw 1 times / day multiple, oral dose: 5 mg/kg bw route of administration: Oral experiment type: MULTIPLE co-administered:	ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
86% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29735566/	unknown, unknown		ISONIAZID plasma	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: https://pubmed.ncbi.nlm.nih.gov/1257824 Page: p.294	healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1257824 Page: p.294	Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea Vomiting Grand mal seizure Lethargy Coma Sources: https://pubmed.ncbi.nlm.nih.gov/1257824 Page: p.294
20 g single, oral Overdose Dose: 20 g Route: oral Route: single Dose: 20 g Sources: https://pubmed.ncbi.nlm.nih.gov/1257824 Page: p.295	healthy, 16 n = 1 Health Status: healthy Age Group: 16 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1257824 Page: p.295	Disc. AE: Nystagmus, Hyperreflexia... AEs leading to discontinuation/dose reduction: Nystagmus Hyperreflexia Sources: https://pubmed.ncbi.nlm.nih.gov/1257824 Page: p.295
112 mg/kg single, oral (max) Overdose Dose: 112 mg/kg Route: oral Route: single Dose: 112 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/9490997	unhealthy, 17 n = 1 Health Status: unhealthy Condition: Tuberculosis Age Group: 17 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/9490997	Disc. AE: Lethargy, Seizures... AEs leading to discontinuation/dose reduction: Lethargy Seizures Coma Tachycardia Sources: https://pubmed.ncbi.nlm.nih.gov/9490997
25 g single, oral Overdose Dose: 25 g Route: oral Route: single Dose: 25 g Co-administed with:: pyridoxine, p.o(2.5 mg, single) Sources: https://pubmed.ncbi.nlm.nih.gov/25779481 Page: p.2	healthy, 20 n = 1 Health Status: healthy Age Group: 20 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/25779481 Page: p.2	Disc. AE: Generalized tonic-clonic seizure... AEs leading to discontinuation/dose reduction: Generalized tonic-clonic seizure Sources: https://pubmed.ncbi.nlm.nih.gov/25779481 Page: p.2
900 mg 1 times / week multiple, oral Recommended Dose: 900 mg, 1 times / week Route: oral Route: multiple Dose: 900 mg, 1 times / week Co-administed with:: rifapentine, p.o(900 mg; 1/week) Sources: https://pubmed.ncbi.nlm.nih.gov/22150035 Page: p.2160	unhealthy, 25–47 n = 3986 Health Status: unhealthy Condition: Tuberculosis Age Group: 25–47 Sex: M+F Population Size: 3986 Sources: https://pubmed.ncbi.nlm.nih.gov/22150035 Page: p.2160	Disc. AE: Hepatotoxicity, Hypersensitivity... AEs leading to discontinuation/dose reduction: Hepatotoxicity (0.3%) Hypersensitivity (2.9%) Sources: https://pubmed.ncbi.nlm.nih.gov/22150035 Page: p.2160
3000 mg single, oral Overdose Dose: 3000 mg Route: oral Route: single Dose: 3000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/3337420 Page: 73/127	healthy, 7 n = 1 Health Status: healthy Age Group: 7 Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/3337420 Page: 73/127	Disc. AE: Seizures, Metabolic acidosis... AEs leading to discontinuation/dose reduction: Seizures (severe) Metabolic acidosis Coma Oliguria Sources: https://pubmed.ncbi.nlm.nih.gov/3337420 Page: 73/127
900 mg 3 times / week multiple, oral Recommended Dose: 900 mg, 3 times / week Route: oral Route: multiple Dose: 900 mg, 3 times / week Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf Page: p.1	unhealthy Health Status: unhealthy Condition: Tuberculosis Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf Page: p.1	Disc. AE: Hepatitis... AEs leading to discontinuation/dose reduction: Hepatitis (grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008678s028lbl.pdf Page: p.1

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	inhibitor 1318	inhibitor 1421

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2C19 1215 CYP3A 175 CYP2E1 761 CYP1A2 1268 CYP2A6 594		CYP2E1 116

Drug as perpetrator

Target	Modality	Activity
CYP2C9 1362	inhibitor 2614 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki 102 uM]
CYP2E1 841	inhibitor 2614 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki 110 uM]
CYP2D6 1455	inhibitor 2614 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki 126 uM]
CYP2C19 1277	inhibitor 2614 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki 13 uM]
CYP3A 244	inhibitor 2614 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki 51.8 uM]
CYP2A6 625	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/11868802/	yes [Ki 60 uM]
CYP1A2 1406	inhibitor 2614 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC90302/	yes [Ki >1000 uM]
CYP2E1 841	inducer 1333 Sources: https://pubmed.ncbi.nlm.nih.gov/8354023/	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY445177	https://www.001chemical.com/chem/54-85-3
3B Scientific (Wuhan) Corp	3B1-00315	http://www.3bsc.com/index/pro_info.php?id=20527
3B Scientific (Wuhan) Corp	3B3-029741	http://www.3bsc.com/index/pro_info.php?id=50998
AA Blocks	AA00I9KA	http://www.aablocks.com/goods/Goods/detail?id=AA00I9KA
AEchem Scientific Corp., USA	AE065418	https://www.aechemsc.com/info_products/AE065418.php
AHH Chemical co.,ltd	MT-16053	http://www.ahhchemical.com/product/MT-16053.html
AK Scientific, Inc. (AKSCI)	65478	http://www.aksci.com/item_detail.php?cat=65478
Aaron Chemicals	AR00IAC2	http://www.aaronchem.com/54-85-3
AbMole Bioscience	M5713	http://www.abmole.com/products/isoniazid.html
Acadechem	ACDS-026244	http://www.acadechemical.com/product/100943
Accela ChemBio Inc	SY010614	http://www.accelachem.com/cn/search.html?keyword=SY010614&attname=GoodsCode
Achemica	ACMC-209ljq	http://www.achemica.com/prodinfo/?id=128880
Achemo Scientific Limited	AC-65231	http://www.achemo.com/search/?Keyword=54-85-3
Achemtek	0102-025873	http://www.achemtek.com/54-85-3
Acros Organics	AC122600050	https://www.fishersci.com/shop/products/isonicotinic-acid-hydrazide-99-acros-organics/AC122600050
Acros Organics	AC122601000	https://www.fishersci.com/shop/products/isonicotinic-acid-hydrazide-99-acros-organics/AC122601000
Acros Organics	AC122605000	https://www.fishersci.com/shop/products/isonicotinic-acid-hydrazide-99-acros-organics/AC122605000
Alfa Aesar	A10583	https://www.alfa.com/en/catalog/A10583/
Alfa Chemistry	AP54853-A	https://reagents.alfa-chemistry.com/product/isoniazid-cas-54-85-3-12958.html
Alfa Chemistry	AP54853-B	https://reagents.alfa-chemistry.com/product/isoniazid-cas-54-85-3-12959.html
Alichem	29206165	http://www.alichem.com/en/products/54-85-3.html
Alsachim	820	http://www.alsachim.com/product-C3287-glo.bal-view.html
Angene	AGN-PC-04X6J8	http://www.angenechemical.com/productshow/AGN-PC-04X6J8.html
Anward	ANW-32196	http://www.anward.com/pro_result/24734
ApexBio Technology	B1957	http://www.apexbt.com/isoniazid.html
Ark Pharm	AK-46317	http://www.arkpharminc.com/products/54-85-3.html
Aronis	ARONIS25141	http://www.aronis.ru/store/index.php?main_page=product_info&cPath=1&products_id=18034
Aurora Fine Chemicals LLC	A00.156.063	http://online.aurorafinechemicals.com/info?ID=A00.156.063
Aurum Pharmatech LLC	T7976	http://www.Aurumpharmatech.com/Product/ProductDetails/T7976
Avantor Inc	200012-850	https://us.vwr.com/store/product/7514538/isoniazid
BLD Pharm	BD21389	http://www.bldpharm.com/products/54-85-3.html
BOC Sciences	774596-24-6	https://www.bocsci.com/isoniazid-d4-cas-774596-24-6-item-133736.html
BioChemPartner	BCP13791	http://www.biochempartner.com/54-85-3-BCP13791
BioCrick	BCC9003	http://www.biocrick.com/Isoniazid-BCC9003.html
Boerchem	BC204682	http://www.boerchem.com/?product_40616.html
CSNpharm	CSN12770	https://www.csnpharm.com/products/isonicotinic-acid-hydrazide.html
Chem Scene	CS-2371	http://www.chemscene.com/54-85-3.html
ChemMol	44001914	http://www.chemmol.com/chemmol/44001914.html
ChemMol	49417216	http://www.chemmol.com/chemmol/49417216.html
ChemMol	99102376	http://www.chemmol.com/chemmol/99102376.html
Chemenu	CM110204	http://www.chemenu.com/products/CM110204
Chemspace	CSSB00000189768	https://chem-space.com/CSSB00000189768
Clearsynth	CS-O-10901	https://www.clearsynth.com/en/CSO10901.html
DC Chemicals	DCAPI1242	http://www.dcchemicals.com//product_show-Isoniazid_Tubizid_.html
Enamine	Z58981801	https://www.enaminestore.com/catalog/Z58981801
Finetech	FT-0627424	http://www.finetechnology-ind.com/prod/detail/pub/54-85-3.html
Finetech	FT-0670476	http://www.finetechnology-ind.com/prod/detail/pub/774596-24-6.html
Glentham Life Sciences	GA2329	http://www.glentham.com/products/product/GA2329/
Hairui	HR135335	http://www.hairuichem.com/en/product/54-85-3.html
LGC Standards	MM1529.00-0250	https://www.lgcstandards.com/US/en/p/MM1529.00-0250
Lab Network	LN00221458	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00221458
Matrix Scientific	127307	https://www.matrixscientific.com/127307.html
MedChem Express	HY-B0329	https://www.medchemexpress.com/Isoniazid.html
Molcore	MC445177	https://www.molcore.com/product/54-85-3
Oakwood	236758	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=117757&ExtHyperLink=1
Parchem	29182	http://www.parchem.com/chemical-supplier-distributor/Isoniazide-019182.aspx
Renno Tech	RP01120	http://www.rennotech.com/product_show.asp?id=7507
Sigma-Aldrich	75182_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/75182?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	I0500000_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/i0500000?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	I3377_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/i3377?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	PHR1932_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/phr1932?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	1349706_USP	https://www.sigmaaldrich.com/catalog/product/usp/1349706?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S010587	http://www.sinfoobiotech.com/product/1013985
Smolecule	S530930	http://www.smolecule.com/products/s530930
TCI (Tokyo Chemical Industry)	I0138	http://www.tcichemicals.com/eshop/en/us/commodity/I0138/index.html
THE BioTek	bt-272339	https://www.thebiotek.com/product/inhibitors/bt-272339
VladaChem	VL142924	https://www.vladachem.com/product.php?products=54-85-3
VladaChem	VL163436	https://www.vladachem.com/product.php?products=54-85-3
VladaChem	VL268039-100G	https://www.vladachem.com/product.php?products=54-85-3
abcr GmbH	AB117136	http://www.abcr.com/shop/en/AB117136
eNovation Chemicals	D386801	http://www.enovationchem.com/productDetails.asp?productID=D386801
eNovation Chemicals	D589900	http://www.enovationchem.com/productDetails.asp?productID=D589900
iChemical	EBD955	http://www.ichemical.com/products/54-85-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-6324947959	https://mcule.com/MCULE-6324947959/

PubMed

Title	Date	PubMed
Hepatotoxicity of rifampicin and isoniazid in children.	1975 May	1079531
Antituberculosis activity of certain antifungal and antihelmintic drugs.	1999	10707260
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.	1999 Dec	10582897
High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.	1999 Dec	10582883
Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.	1999 Feb 25	10066642
[A case of pulmonary tuberculosis with acute renal failure caused by readministration of rifampicin].	1999 Nov	10599213
Antimycobacterial activity of new ortho-, meta- and para-toluidine derivatives.	1999 Nov-Dec	10668170
Drug-induced lupus nephritis in HIV infection.	1999 Oct	10534557
Outcome of multidrug-resistant tuberculosis in human immunodeficiency virus-infected patients.	1999 Sep	10530447
Activity of moxifloxacin against mycobacteria.	1999 Sep	10511409
Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa.	2000	10897383
Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999.	2000 Apr	10764337
Antimycobacterial activities of novel levofloxacin analogues.	2000 Aug	10898685
Acute isoniazid neurotoxicity during preventive therapy.	2000 Feb	10708202
Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs.	2000 Feb 1	10609550
[Isoniazid-induced hepatic failure. Report of a case].	2000 Jan-Mar	10962632
Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis.	2000 Jul	10869086
Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid.	2000 Jul 4	10869170
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs.	2000 Jun	10837441
Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals.	2000 Mar 31	10780724
Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis.	2000 Nov	11069675
Antepartum or postpartum isoniazid treatment of latent tuberculosis infection.	2000 Nov	11042314
Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.	2000 Sep	10952625
On-column amperometric detection of ofloxacin and pasiniazid in urine by capillary electrophoresis with an improved fractured joint and small detection cell.	2001 Apr	11340975
Evaluation of tuberculosis control by periodic or routine susceptibility testing in previously treated cases.	2001 Apr	11334251
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.	2001 Apr 20	11330495
Ion interaction reagent reversed-phase high-performance liquid chromatography determination of anti-tuberculosis drugs and metabolites in biological fluids.	2001 Apr 25	11339291
[Disseminated disease by Mycobacterium kansasii resistant to isoniazid and rifampin in patients] with AIDS].	2001 Feb	11333577
Connatal tuberculosis in an extremely low birth weight infant: case report and management of exposure to tuberculosis in a neonatal intensive care unit.	2001 Feb	11271396
TB prevention in HIV clinics in New York City.	2001 Feb	11258505
Drug-resistant tuberculosis in Taipei, 1996-1999.	2001 Feb	11172317
Incentives vs outreach workers for latent tuberculosis treatment in drug users.	2001 Feb	11165450
Outbreak of multidrug-resistant tuberculosis at a methadone treatment program.	2001 Jan	11263518
Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy.	2001 Jan	11263515
Prevalence of drug-resistant tuberculosis in an HIV endemic area in northern Thailand.	2001 Jan	11263513
Does tuberculosis after kidney transplantation follow the trend of tuberculosis in general population?	2001 Jan	11256535
Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started?	2001 Jan	11243745
Survey for tuberculosis in a tribal population in North Arcot District.	2001 Mar	11326823
Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines.	2001 Mar	11282269
Mycobacterial FurA is a negative regulator of catalase-peroxidase gene katG.	2001 Mar	11251835
First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.	2001 Mar	11182006
Active site structure of the catalase-peroxidases from Mycobacterium tuberculosis and Escherichia coli by extended X-ray absorption fine structure analysis.	2001 Mar 9	11257507
Experimental in vitro efficacy study on the interaction of epiroprim plus isoniazid against Mycobacterium tuberculosis.	2001 Mar-Apr	11173814
Efficacy of chemotherapy for prostatic tuberculosis-a clinical and histologic follow-up study.	2001 May	11337284

Patents

Sample Use Guides

In Vivo Use Guide

Adults: 5 mg/kg up to 300 mg daily in a single dose; or 15 mg/kg up to 900 mg/day, two or three times/week Children: 10 mg/kg to15 mg/kg up to 300 mg daily in a single dose; or 20 mg/kg to 40 mg/kg up to 900 mg/day, two or three times/week

Route of Administration: Oral

In Vitro Use Guide

1.56 μg/ml

Name

Type

Language

ISONIAZID

Official Name

English

HYDRAZID

Common Name

English

ISONIAZID COMPONENT OF RIFATER

Common Name

English

ISOBICINA

Common Name

English

ERALON

Common Name

English

4-PYRIDINECARBOXYLIC ACID, HYDRAZIDE

Common Name

English

INH

Brand Name

English

STANOZIDE

Brand Name

English

ISONIAZID [USP MONOGRAPH]

Common Name

English

HYZYD

Brand Name

English

ISONICOTINIC ACID HYDRAZIDE

Systematic Name

English

MYBASAN

Common Name

English

NYDRAZID

Brand Name

English

4-PYRIDINECARBOXYLIC ACID HYDRAZIDE [WHO-IP]

Common Name

English

CEDIN

Common Name

English

ISONIAZID [ORANGE BOOK]

Common Name

English

ATCOTIBINE

Common Name

English

ISONIAZID [JAN]

Common Name

English

ISONIAZID [WHO-DD]

Common Name

English

COTINAZIN

Common Name

English

RIMIFON

Brand Name

English

DITUBIN

Common Name

English

ARMAZID

Common Name

English

NEUMANDIN

Common Name

English

IPCAZIDE

Common Name

English

TEEBACONIN

Common Name

English

ISONIAZID [EP MONOGRAPH]

Common Name

English

ISONICOTINIC ACID HYDRAZIDE [WHO-IP]

Common Name

English

ISONIAZID [USP-RS]

Common Name

English

ISONIAZID COMPONENT OF RIFAMATE

Common Name

English

HIDRASONIL

Common Name

English

ISONIAZID [WHO-IP]

Common Name

English

DINACRIN

Common Name

English

ISONIAZID [MI]

Common Name

English

ISONIAZID [INN]

Common Name

English

RIFAMATE COMPONENT ISONIAZID

Common Name

English

ISONIAZID [MART.]

Common Name

English

ARMAZIDE

Common Name

English

NSC-9659

Code

English

ERTUBAN

Common Name

English

ISONIAZIDUM [WHO-IP LATIN]

Common Name

English

RIFATER COMPONENT ISONIAZID

Common Name

English

ISONICOTINYLHYDRAZINE

Systematic Name

English

TISIODRAZIDA

Common Name

English

DIANICOTYL

Common Name

English

DOW-ISONIAZID

Brand Name

English

ISONICOTINIC ACID HYDRAZIDE [IARC]

Common Name

English

ISONIAZID [EP]

Common Name

English

ISONIAZID [HSDB]

Common Name

English

ISONICOTAN

Common Name

English

ISCOTIN

Brand Name

English

ISONIAZID [VANDF]

Common Name

English

ISIDRINA

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175483